Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196912 | 0.77 | PARP1 (0.42) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL3232202 | 0.76 | PARP1 (0.41) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL8668 | 0.74 | PARP1 (0.56) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL4130388 | 0.74 | PARP1 (0.56) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL30036694 | 0.74 | PARP1 (0.43) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL1445123 | 0.74 | PDPK1 (0.41) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL312428 | 0.74 | PARP1 (0.43) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL1019602 | 0.74 | QPCT (0.42) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL196737 | 0.74 | PARP1 (0.56) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL13857865 | 0.74 | PARP1 (0.39) | PARP1SMN1; SMN2PDPK1CA12ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108752328-A | A kind of method of easy synthesis Azilsartan | 常州大学 | 2018-11-06 | — | — | CN | disclosed |
| CN-105531265-B | Pesticidal compounds | 巴斯夫欧洲公司 | 2018-07-20 | — | — | CN | disclosed |
| CN-107872977-A | The combination product of IRAK4 inhibitor and BTK inhibitor | 拜耳制药股份公司 | 2018-04-03 | — | — | CN | disclosed |
| CN-104230909-B | A kind of preparation method of Azilsartan | 中国人民解放军第二三○医院 | 2018-01-09 | — | — | CN | disclosed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-7790882-B2 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick M. (CH) | 2010-09-07 | — | — | US | disclosed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1773853-A1 | MONOPHOSPHINE COMPOUNDS, TRANSITION METAL COMPLEXES THEREOF AND PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS USING THE COMPLEXES AS ASYMMETRIC CATALYSTS | Sumitomo Chemical Company, Limited (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20060135447-A1 | Macrolides | CHUPAK LOUIS S | 2006-06-22 | — | — | US | disclosed |
| WO-2005121157-A1 | MONOPHOSPHINE COMPOUNDS, TRANSITION METAL COMPLEXES THEREOF AND PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS USING THE COMPLEXES AS ASYMMETRIC CATALYSTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick (CH) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135447-A1 | Macrolides | LCAT, NOP2, HDAC6 | PARP1 2928/4885SMN1; SMN2 673/4885PDPK1 3566/4885 |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | C1R, ARL1, C5 | PARP1 1497/4885SMN1; SMN2 4700/4885PDPK1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.